Radioactive therapy for resistant neuroblastoma and pheochromocytoma
Part of Cancer clinical trials.
This trial uses a radioactive medicine called 131I-MIBG to treat neuroblastoma or pheochromocytoma that has come back or not responded to standard treatment. The treatment targets and damages cancer cells while trying to spare healthy tissue.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neuroblastoma or pheochromocytoma that has returned or not improved with standard treatment.
- Your tumor shows uptake of a special scan (MIBG) within the last 6 weeks.
- At least 2 weeks since your last chemotherapy that affects blood counts, and at least 3 months since certain types of radiation.
- Your blood counts and organ function (kidney, liver, heart, lungs) meet minimum levels.
- You have stored stem cells available for a stem cell rescue after the treatment.
- You are not pregnant or breastfeeding, and you do not have an active serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial gives a radioactive drug called 131-I-MIBG to treat neuroblastoma that has not gone away or has come back. The drug targets cancer cells, and stem cells are given back after treatment to help the body recover.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This trial tests a new type of radiation therapy for advanced neuroendocrine cancers that have not responded to standard treatments. It aims to see if this therapy can help shrink or control the cancer.
This trial is testing whether adding a vaccine to a substance called beta-glucan (which may help the immune system) and a growth factor drug called GM-CSF can help prevent high-risk neuroblastoma from coming back. You would receive these as an injection or IV. The study is for people whose cancer is in remission or has responded well to prior treatment.
This trial provides access to a radioactive medicine called 131I-MIBG for people with certain nerve tumors that have returned or not responded to standard treatment. The treatment targets and kills cancer cells, and it may help when other options have not worked.
This trial uses a radioactive medicine called MIBG to target and kill neuroblastoma or related tumor cells that have not responded to standard treatments. It may help patients whose cancer has come back or is hard to treat.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.